The DOSE Study
Study Overview
The DOSE Study is an open-label randomized trial of daily doxycycline (100mg daily) versus weekly doxycycline (200mg weekly) versus event-driven doxycycline (200mg within 72 hours of STI exposure; standard of care) for STI prevention among men who have sex with men (MSM) engaging in chemsex. Participants will attend quarterly follow-up visits over 12 months for assessment of HIV, bacterial STIs (GC/CT and syphilis), adherence, substance use, and sexual behaviors. All participants who test positive for an STI will receive treatment and undergo repeat testing to document clearance of infection.
Study Product
Doxycycline is an antibiotic that is currently being used as event-driven doxyPEP in clinical practice.
Eligibility
1) Born Male
2) Age ≥ 18 years old
3) History of Meth use while sexually active